rnai juggernaut move onward upward
initi outperform
initi coverag outperform rate price target
leader grow rnai therapeut space launch first product
featur promis late-stag asset larg unmet need possess
deep earli pipelin expans collabor w/regn hold upsid
near-term commerci newsflow believ expect onpattro global
launch least meet expect vitrusiran ph offer opportun
expand transthyretin amyloidosi footprint best-in-class franchis time
anticip lumasiran ph meet success quarter givosiran
approv believ rnai technolog evolut adequ address prior
safeti stumbl support posit outlook platform-to-product viabil
attr opportun expand franchis evolut project
continu growth onpattro hattr polyneuropathi every-three-week iv
least meet expect geograph expans increas diagnos
oral vyndaqel appear take major initi share larger
hattr cardiomyopathi popul see once-quarterli sc vutrisiran ph data
posit treatment-of-choic
newsflow intern partner develop asset next
month see lumasiran ph data primari hyperoxaluria initi
vutrisiran ph trial attr cardiomyopathi inclisiran nda file
hypercholesterolemia partner mdco givosiran approv acut
hepat porphyria patisiran ph data mix attr cardiomyopathi
substanti valu potenti held earli broad clinic portfolio
indic includ complement-medi diseas antitrypsin
defici hepat hypertens explor
histor difficult drug non-liv disord ocular potenti
n-t mileston door open novel deliveri technolog
program toward target anticip advanc five-year
platform evolut come safeti comfort signific unpredict
toxic encount alni earlier-gener candid kept mani
invest rnai asset featur newer technolog esc-conjug
galnac shown less worrisom safeti issu mainli consist low rate
infus reaction routin manag advanc
also result increas potenc allow less-frequ dose
see share inexpens late-stag pipelin alon forecast
sale respect
year price histori alnylam
alnylam onpattro becam
compani advanc pipelin
innov rnai-bas medicin
hepat infecti diseas central
nervou system ocular
analyst certif import disclosur see disclosur
see trade attract price given
late-stag clinic pipelin domin posit rnai
landscap expect potenti best-in-class transthyretin
amyloidosi franchis primari valu driver year
come appreci substanti valu potenti held
earli broad clinic portfolio includ non-liv target
believ prior safeti issu encount w\ith rnai
address suffici enabl viabl drug candid
believ share upsid continu grow
onpattro commerci advanc program
lumasiran succe phase program
givosiran approv ahp on/around
attr franchis sale grow beyond out-year est
pipelin asset current valu advanc develep
 day nyc
lumasiran top-lin ph data
initi helios-b trial vitrusiran
givosiran pdufa ahp
lumasiran fail pivot develop
vitrusiran fail pivot develop
deriv price target sum-of-the-part methodolog market pipelin product alnylam portfolio
market near-market product use discount cash flow valuat employ weight averag cost capit wacc
risk adjust vutrisiran lumasiran inclisiran givosiran termin valu base termin
growth rate ev/revenu multipl earlier develop candid assign pipelin valu cover expect
potenti pipelin platform whole price target calcul use share outstand account dilut
share one year
risk includ onpattro launch underwhelm expect vitrusiran fail succeed develop unexpect toxic
observ onpattro commerci set cash burn higher expect
tabl content
polyneuropathi hereditari transthyretin-medi amyloidosi
alnylam pioneer field rna interfer rnai form basi
therapeut program although earlier effort leverag cellular
mechan treat diseas stumbl sever disapoint relat
safeti well efficaci opinion suffici advanc
technolog gener viabl drug develop specif
compani platform innov appear adequ address deliveri
potenc challeng inher use drug consist rna target
liver circul protein made furthermor earli result
indic promis potenti compani innov enabl target
rna drug organ
support favor view last year approv first rnai drug alni
onpattro patisiran launch global treat polyneuropathi associ
rare disord hereditari transthyretin amyloidosi hattr onpattro
sale gate low versu initi expect believ futur
trajectori least meet current estim may upsid
increas diagnosi rate estim peopl world-wide
hattr experi polyneuropathi onpattro
indic treat hattr cardiomyopathi affect approxim
shown evid cardiac improv clinic trial recent initi phase
trial design enabl potenti expans indic
howev onpattro first step toward attr franchis
build develop vutrisiran next-gener rnai posit
serv comer potenti patient includ hattr
cardiomyopathi well neuropathi also much larger popul
non-hereditari form known wild-typ attr estim
peopl wtattr world-wide moreov believ vutrisiran need
dose four time year subcutan shot versu onpattro once-
every-three-week intraven infus make competit
pfizer tafamidi once-daili oral work non-rnai mechan
approv earlier year hereditari wild type attr patient
cardiomyopathi kol weve spoken tend view rnai approach
clinic superior conced tafamidi conveni meaning
advantag vutrisiran enter broad phase program attr
although vutrisiran phase data lie year away view candid
rel de-risk best-in-class treatment type transthyretin
amyloidosi optimist succ broad pivot develop
believ vutrisiran enabl eventu take lion share overal
nearer term highlight activ calendar newsflow around late-stag
pipelin candid year-end see top-lin phase data
lumasiran primari hyperoxaluria februari see givosiran
approv acut hepat porphyria would expect posit outcom
increas investor comfort rnai area gener
candid pois serv market togeth onpattro
allow approach cash flow break-even time frame
inclisiran fitusiran partner medicin compani mdco
sanofi-genzym sni respect mid- high-teen royalti inclisiran
inhibit product valid target lower mdco
expect submit nda quarter hypercholesterolemia manag
follow broadli posit phase result fitusiran inhibit product anti-
thrombin key player blood coagul believ fitusiran
small commerci opportun rel alni advanc candid may
find use hemophilia patient develop inhibitor
compani early-stag rnai pipelin consist sever asset
highlight allianc enter earlier year bring alni
technolog bear diseas area expertis includ
eye central nervou system non-liv target histor
nearli imposs address rnai appear may crack
problem innov
alni platform drug asset protect formid intellectu
properti estat provid high degre exclus protect
believ compani may experi near-term volatil competit
enrol wtattr patient would repres attract entri point
investor wish share expect one
premier biotech compani come decad
valuat deriv sum-of-the-part methodolog
market pipelin product alnylam portfolio market near-
market product use discount cash flow valuat employ
weight averag cost capit wacc risk adjust vutrisiran
lumasiran inclisiran givosiran termin valu
base termin growth rate ev/revenu multipl earlier
develop candid assign pipelin valu cover expect
potenti pipelin platform whole price target
calcul use share outstand account dilut share one year
downsid risk price target includ inabl maintain price
onpattro label expand wtattr unforeseen issu gal-nac
conjug system failur defin new molecular target meaning
expand pipelin failur becom cash flow posit timelin
expect failur either givosiran lumasiran receiv fda approv
potenti upsid catalyst price target includ acceler onpattro
sale hattr greater penetr wtattr modest expect
rapid approv vutrisiran wtattr popul earli pipelin asset
progress faster expect realiz greater valu assign
exhibit valuat
see out-performance share next month catalyz
posit read-through pipelin data
commerci revenu growth slow cash burn
phase read-out treatment primari hyperoxaluria
year end pdufa acut hepat porphyria earli februari also
expect updat acceler earli pipelin element late year
may give us line sight commerci date see result
read-through rest pipelin expect investor interest
acceler posit catalyst compound alnylam progress toward cash
productev timingimpact top-line pipelin complet complet complet expans toward readout readout outperform
industri leader develop
commerci therapeut base rna interfer rnai
exclus focus rnai strategi treat diseas sinc
compani found shortli follow discoveri biolog
process rnai refer inhibit gene express target
neutral messeng rna mrna prevent translat encod
protein mechan use essenti human cell control
much given protein get made therapeut act rnai
prevent occurr problemat protein first place upstream
convent drug small molecul antibodi gener act
alni platform enabl gener small interf rna sirna drug
effici deliv liver cell potent select
silenc disease-caus gene compani proprietari technolog consist
innov enabl subcutan administr vs intraven infus
less frequent dose recent enhanc appear promis non-hepat
deliveri sirna potenti address disord organ
brain eye
compani recent commerci first product onpattro approv treat
polyneuropathi occur hereditari transthyretin amyloidosi hattr
debilit often fatal rare disord onpattro launch us
japan launch country-by-countri europ expect expand
global geograph approv secur partner
corp offer free genet test maintain patient assist program
facilit reimburs provid support onpattro late-stag
develop potenti label expans treat cardiomyopathi
hereditari well non-hereditari wild-typ form
attr may repres improv onpattro vutrisiran given
subcutan inject everi three month contrast onpattro everi three
week intraven infus favor safeti profil evolv
time alni attr franchis posit address major patient
condit irrespect biolog caus symptom
wholli own candid near commerci givosiran potenti
approv acut hepat porphyria lumasiran phase data
primari hyperoxaluria type report
late-stag asset partner develop
commerci includ inclisiran hypercholesterolemia licens
medicin compani fitusiran hemophilia licens sanofi-genzym
portfolio early-stag asset pursu treatment
diseas result disord complement system well
defici antitrypsin addit hepat hypertens
support recent non-clin observ compani believ abl
overcom challeng deliv rnai treatment non-liv target
potenti open door multipl ocular indic
histor difficult drug use rnai strategi
histori rnai
rna interfer first describ paper andrew fire craig
mello professor stanford univers univers massachusett
medic school respect describ rna involv post-
transcript gene silenc rnai rapidli becam subject attent
drug develop becam new darl therapeut modal mani larg
pharmaceut compani paper author nobel prize
unfortun initi new drug develop concept first clinic
trial met unexpect issu issu revolv around immune-rel
toxic off-target cellular effect organ-target specif endosom
escap singl biggest issu revolv around develop rnai
alway deliveri second gener rnai therapeut involv
deliveri use lipid nanoparticl nanoparticl improv deliveri
poor side effect profil well wave failur led exit mani
pharmaceut compani develop rnai therapi put
signific pressur fund compani left
research space
still work rnai therapeut abl find way address
issu via structur motif sequenc select cell ligand target
specif one way attach n-acetylgalactosamin
galnac conjug structur motif protect stabil rna strand
cleav move circul galactosamin portion allow
tissu specif bind uptak liver cell exclud onpattro use
lipid nanoparticl deliveri system alnylam entir platform util galnac
technolog stabil improv earlier stage develop asset
outflux compani oper rnai space led signific
consolid compani opportun capit massiv
potenti lie within rnai therapeut alnylam class leader
market capit major compani market cap
rnai antisens oligonucleotid asset includ
immunogen rnai therapi expect larg control
target liver thank galnac-esc platform ioni also antisens
oligonucleotid approv transthyretin amyloidosi
tradenam tegsedi function similar rnai lead degrad
target mrna strand howev retain great deal immunolog side effect
implic caus thrombocytopenia kidney failur alnylam
esc evolut platform expect stabil rnai molecul
even lower side effect profil
mechan action rnai
sirna rnai sequenc complementari target specif
mrna dsrna interfer unwound protein call dicer
complementari function strand bind complex rnai trigger may
variabl length target specif base-pair bp sequenc trigger
larger bp rna duplex cleav enzym refer dicer
trigger rna duplex smaller bp may abl function without
dicer involv dicer cleav rna handoff complex refer
rna-induc silenc complex risc risc direct degrad target
mrna use catalyt activ argonaut protein mrna
would normal transcrib produc protein involv target protein
suspect involv diseas state degrad mrna
halt translat express encod protein
exhibit rnai mechan action
compani public rna interfer
deliveri method rnai
premier challeng involv rnai get function drug target
site rnai need protect variou nucleas
would cleav throughout bodi also must abl reach
produc cell intact deliv target sequenc absolut must
produc signific immun respons design molecul must
account avoid immun system mani compani attempt
variou mean protect deliv rnai molecul process
first gener rnai deliveri success lipid nanoparticl
current state futur direct rnai-bas therapeut setten
commerci viabl form emerg lipid nanoparticl lnp
form galnac conjug gapmer single-strand
design ioni liver deliveri ioniss inotersen enter cell poorli
understood mechan bind mrna degrad rnase
nucleu cell lack specif target ioniss molecul
contribut system side effect failur compani make
viabl lnp continu side effect profil mani other
demonstr superior alnylam scienc technolog alnylam
pipelin continu evolv deliveri method lnp esc-galnac
esc -galnac new yet-to-be-releas target ligand eye
exhibit differ esc esc exhibit
onpattro patisiran first rnai therapi approv use design
treat hattr administ everi week iv lipid
nanoparticl formul second-gener pegyl lnp contain
cholesterol polar lipid pegyl lipid ioniz amino lipid amino
lipid neutral charg becom cation acid condit
liver hepatocyt take lnp send endosom acid
ph induc ioniz amino lipid compon lead disassembl
lnp releas rnai therapeut within hepatocyt
exhibit overview onpattro
current state futur direct rnai-bas therapeut setten
exhibit nice outlin mechan action patisiran show
lipid nanoparticl deliveri mechan antisens strand effect
halt product ttr liver also show pathogen state
mutant ttr dissembl monom misfold aggreg amyloid
deposit variou organ system bodi
second-gener lipid nanoparticl formul onpattro
quit ideal drug due potenti immune-rel reaction order
counteract onpattro administ cocktail pre-med
corticosteroid antihistamin acetaminophen suppress immun respons
rnai distribut infusion-rel reaction still occur upon
administr directli result less patient withdraw
clinic trial exclud infus relat reaction onpattro gener well
toler role transport vitamin thyroxin vitamin
defici occur potenti side effect seen less patient
includ upper respiratori tract infect indigest short breath muscl
spasm joint pain erythema dizzi despit patient
treatment arm trial withdrew treatment earli
placebo-tr patient withdrew treatment consent phase studi
onpattro improv highli statist signific p-
score
transthyretin name role transport thyroxin thyroid hormon
retinol vitamin transthyretin amyloidosi either wild-typ
hereditari condit caus dissoci misfold
transthyretin molecul monom amyloid protein
aggreg bodi form amyloid fibril onpattro block product
mutant wild-typ transthyretin reduc overal number
bodi reduc number amyloid protein function protein
hereditari attr present multipl fashion primari way
manifest diagnosi cardiomyopathi polyneuropathi
diseas formerli thought separ diseas certain mutat type
lead certain present mostli true patient eventu
symptomat deposit organ across genotyp
fda still diseas segment pn cm base histor
understand diseas common present
cardiomyopathi expect popul us compar
popul neuropathi approxim
diagnos part polyneuropathi segment cardiac
involv cardiac involv neuropath
current cardiologist best diagnost method typic
biopsi cardiac tissu insert cathet vein neck
technetium pyrophosph scan use may major improv
diagnost effici go forward boast sensit specif
blood urin test use confirm diagnosi howev
primari way diagnosi rate improv greater physician
market size geographi
two market defin evalu attr neither market well
understood hereditari form attr present mutat
bind site ttr one amino acid swap
standard wild-typ amino acid normal present popul
mutat polyneuropathi patient methionin
would normal valin posit also wild-typ
popul mutat still disassembl deposit
amyloid across organ notabl heart
hattr popul quit larg orphan drug popul
segment mutat type differ clinic present alnylam
estim approxim patient world-wide suffer diseas
estim alnylam pursu popul
four major areasth us eu japan brazil
popul rate occurr case per million peopl
eu segment mutat rate base countrysweden
portug endem attr-pn preval rate
japan also area endem othersth nagano
kumamoto region elev rate hattr case per million
case per million respect diseas typic age onset
year age alnylam expect japan second-largest market
countri planet end
popul gener older deposit amyloid protein due
age approxim popul year old signific
amyloid deposit preval elderli popul though
mani patient cardiac symptom earli late
present amyloid deposit undergo biopsi model
modestli penetr rate wild-typ patient popul
expect use elderli popul
assum low diagnosi rate low penetr signific upsid
number potenti penetr size popul also carri
risk price pressur
expect market size wild-typ potenti expand beyond even current
expect util pyp estim
heart failur patient could signific build-up amyloid protein impli
potenti us market high visibl clinic
exhibit progress variou therapeut agent attr-pn
current treatment hattr involv symptomat palli care
administr transthyretin stabil administr antisens
oligonucleotid see exhibit treatment shown
actual improv progress attr patisiran
current treatment market shown abil slow progress
diseas abl show depth respons onpattro
two major molecul current use physician stabil
attr tafamidi diflunis tafamidi once-daili oral dose mg
price premium annual price tag diflunis gener
use off-label approv hattr treatment drug act
bind ttr thyroxin bind site slow dissoci
monom exhibit tafamidi repres molecul
black stabil tetram
exhibit mechan action ttr stabil
neurolog manifest ttr amyloidosi rezania
data suggest attr popul partial full respond
tafamidi slightli less half classifi full respond
discern diseas progress monteiro et al howev also show
femal far better respond tafamidi men full
respons femal femal full respond
meager men full respond tafamidi unfortun
tafamidi wtattr male-domin diseas case
occur men
addit ttr stabil current use phase
trial molecul eido term propos
super stabil transthyretin stronger bind affin tafamidi
eido believ molecul stabil capabl mimic natur
occur mutat regard rescu mutat
multipl sourc core tetram propos stabil stronger
hydrogen bond base fold protein paper publish
natur earlier year show free energi calcul indic
mutat directli affect rate tetramer dissoci dimer
eido also shown abil higher ttr serum level tafamidi
point stabil allow longer serum half-lif ttr look
successor tafamidi oral dose enrol expect
major hang-up delay therapi eido trial expect enrol
patient activ placebo ratio trial primari endpoint
evalu chang minut walk test eido also evalu
perform reduc mortal cardiovascular hospit
given similar tafamidi expect outlook eido may
favor may reach market approxim one year
vutrisiran vutrisiran unabl sort acceler approv
believ ultim vutrisiran prove attract option
patient physician drug market base vutrisiran
tegsedi inotersen antisens oligonucleotid current approv
treatment attr see exhibit tegsedi
knockdown genet target compar knockdown onpattro
less attract clinic outcom concern safeti effect exhibit
clinic trial led black box warn regard platelet count
kidney toxic stroke unlik onpattro requir prophylact use
immunosuppress howev talk key opinion leader kol
impli tegsedi major advantag subcutan once-weekli
dose perform patient larg nullifi black box warn
thrombocytopenia requir multipl in-offic blood draw
combin inconveni seriou potenti side effect significantli
hamper tegsedi penetr market
exhibit side effect profil phase studi tegsedi
inotersen treatment patient hereditari transthyretin amyloidosi benson berk waddington-cruz et al
tegsedi weak recept consid option avail
physician gener revenu first three
commerci quarter expect tegsedi minor player attr
among competit dynam import note attr continu
massiv underdiagnos yet tool diagnosi avail physician
awar educ go fundament driver growth
market attr treatment multipl compani fuel market
campaign physician awar drive improv market
whole certainli put best therapi best posit onpattro
yet approv portion popul attr cardiomyopathi
adopt cardiologist see patient polyneuropathi
certainli drive revenu growth addit may inform outlook
vutrisiran approv repres opinion best-in-class option
physician patient
onpattro current approv hereditari form attr
specif subset patient present polyneuropathi
phase trial label expans call apollo-b hattr wtattr patient
cardiomyopathi apollo-b enrol patient wild-typ ttr
mutat may stabil nave stabil progressor must
confirm cardiomyopathi medic histori symptomat heart failur
primari endpoint trial chang walk test month
data trial expect read would enabl expans
far larger patient popul allow access wild type patient
attr patient present cardiomyopathi
expans wtattr patient popul potenti catalyst
massiv revenu gener given enorm potenti preval wtattr
kol spoken opin posit regard onpattro
usag cardiomyopathi wait use commerci
onpattro full approv indic addit tafamidi rapidli
penetr wild-typ market alreadi year ahead also
forese potenti good therapi wtattr popul
forecast modest penetr onpattro vutrisiran popul
acknowledg signific upsid potenti especi vutrisiran enter
vutrisiran phase develop treatment hereditari attr
near term look expand label wild-typ transthyretin amyloidosi
shortli afterward wild-typ attr much common form attr
hereditari predominantli present older men alnylam estim
wtattr patient popul world-wide estim heavili
underdiagnos could present heart failur patient
impli potenti us popul
vutrisiran improv formul patisiran enabl subcutan
dose everi three month util alni galnac technolog
enhanc stabil chemistri also mean requir
immunosuppress regimen prior administr compar favor
patisiran rnai trigger vutrisiran remain patisiran
differ deliveri molecul galnac deliveri mechan
valid givosiran lumasiran rnai trigger valid
patisiran see vutrisiran heavili de-risk
vutrisiran phase trial hattr evalu studi term
helios-a helios-a enrol patient hattr popul helios-a
compar vutrisiran activ compar patisiran time
frame primari outcom measur norfolk qualiti life-
diabet neuropathi vutrisiran also expect enrol patient helios-b
larger wtattr market trial primarili evalu
mortal cv-relat hospit kccq-o nt-probnp
mean left ventricl wall thick notabl secondari endpoint
exhibit trial inform helios-b potenti
alnylam plan util apollo-b studi data onpattro vutrisiran
studi helios-a inform helios-b potenti leverag massiv data set
rapidli move forward vutrisiran approv wtattr patient popul
mention treatment use rnai trigger block
product ttr differ vutrisiran onpattro lie
deliveri mechan vutrisiran use gal-nac conjug onpattro use older
helios-b expect initi late compet apollo-b
enrol well eido tafamidi much competit
wtattr patient multipl trial helios-b enrol patient apollo-b
enrol patient eidoss attribute-cm trial enrol patient
tafamidi remain hurdl trial enrol given approv howev
price tafamidi gone rel restrict access
patient must make co-pay greater may lean toward free
clinic trial treatment option
expect delay initi helios-b assum
end earli mountain data avail rnai trigger helios-b
evalu period primari trial endpoint would
expect interim data trial would complet
givosiran rnai treatment acut hepat porphyria block product
aminolevulin acid synthas respons catalyz
format -aminolevulin acid glycin succinyl-coa first step
heme synthesi liver block initi heme synthesi prevent
typic accumul toxic intermedi due function enzymat issu
heme produc bone marrow inhibit product
liver materi impact hemoglobin myoglobin product
patient givosiran arm phase studi present anemia
acut hepat porphyria ahp group diseas character function
issu enzym format hemoglobin caus ahp
well known appear group factor induc synthesi
may contribut precipit acut attack due build-up
precursor put stress low level enzymat activ mani genet
mutat medic alcohol smoke sex hormon environment stress
diet factor implic precipit acut attack
acut intermitt porphyria largest subset acut hepat porphyria
popul aip caus mutat gene porphobilinogen
deaminas mutat reduc amount function enzym present
lead buildup porphobilinogen period stress precursor
heme product notabl -aminolevulin acid upregul
current treatment lacklust patient administ hemin prophylact
physician may administ hemin carbohydr acut attack start
poor diseas control among popul could contribut lower diagnosi
rate mani patient becom disillus healthcar
system seek altern treatment true treatment improv qualiti
life could bring diagnosi popul statist higher expect
alni envis phase studi givosiran ahp mix result seen
givosiran improv annual attack rate across treatment set
reduc median attack rate patient treatment arm also
attack-fre rate threefold increas placebo
howev number patient present advers event treatment
exceed placebo arm patient vs seriou advers
event even wors treat patient present sae
compar placebo arm ascrib small patient
size placebo treatment arm three sae trial
report relat studi drug case fever case elev liver
enzym upper limit normal case chronic kidney diseas
patient report chronic kidney diseas previou histori
ckd patient clinic signific proteinuria treatment
discontinu due renal ckd commonli seen mani ahp patient
due effect chronic hypertens possibl higher incid
ckd givosiran placebo due constant dysregul
improv may caus transient increas creatinin level
addit ckd presenc patient givosiran arm
elev liver enzym upper limit normal patient
placebo arm patient resolut on-going dose
dose interrupt lower last stop due increas
liver enzym upper limit normal deter patient
patient option continu ole lone
except patient liver enzym elev unabl
exhibit ole data phase patient
note trial complet patient given
option continu ole period patient continu ole
period continu show signific decreas approxim baselin
averag number attack rel number placebo portion
genet test done evalu individu mutat type associ
ahp howev individu pbgd/hmb mutat never develop
symptom mutat remain latent never manifest aip
pbgd mutat rang sever onset diseas alway
stressor caus build-up porphobilinogen though genet test
like improv diagnos may help confirm diagnosi major rout
improv diagnosi rate continu physician educ
order optim diagnosi rate creat partnership
improv diagnosi rate among gastroenterologist
specialist expect see patient ahp earli
diseas progress mani patient present complain abdomin pain
alnylam estim approxim patient suffer ahp
suffer recurr attack research believ
suffer recurr attack us eu
may expand better diagnosi rate given burden
diseas expect mani patient sever recurr
givosiran pdufa data set februari expect full
approv expect launch patient typic healthcar
charg annual project cost along improv
patient care qualiti life price expect believ
gross payment gross-to-net discount result net price
reason consid patient size burden
diseas patient expect peak sale
lumasiran phase studi treatment primari hyperoxaluria type
ultra-orphan autosom recess disord lumasiran fda
breakthrough therapi ema prime design rare diseas
candid alnylam support genet test patient
lumasiran util alni galnac technolog enhanc stabil
condit excess oxal product occur due
defici alanine-glyoxyl aminotransferas result format
recurr kidney stone nephrocalcinosi impair renal function
deplet renal function lead oxal crystal deposit multipl organ
includ bone skin retina heart normal convert glyoxyl
glycin defici lead increas glyoxyl pool excess
substrat lead subsequ product oxal exhibit
vitamin potenti therapi set patient approxim
patient ph type respond pyridoxin therapi
signific reduct urinari oxal excret pyridoxin therapi
continu indefinit liver transplant option
potenti treatment evalu includ reloxalias oxalate-
degrad enzym phase alna rnai product lactat
dehydrogenas phase dcna oxabact microbiom treatment
improv gut level oxalobact formigen consum oxal gut
believ alnylam clear frontrunn treatment
lumasiran function inhibit product glycol oxidas normal
catalyz product oxal glyoxyl inhibit oxal product
lead build-up glycol water solubl subsequ
remov urin
lumasiran complet phase studi month open-label
extens data treatment primari hyperoxaluria shown abil
reduc urin oxal level mean maxim reduct
patient phase studi achiev urinari oxal level
upper limit normal patient achiev normal level urinari
evalu three phase trialsilluminate-a illuminate-b
illuminate-c illuminate-a design show efficaci patient year
older preserv renal function illuminate-a complet enrol june
expect top-lin phase readout end year nda
plan submiss earli assum posit result
illuminate-b evalu patient age six preserv renal
function enrol patient singl group assign current still
enrol alnylam expect enrol complet year-end top-line
result read
illuminate-c evalu pediatr adult patient impair renal
function alnylam expect initi ill-c late
primari hyperoxaluria affect peopl world-wide
case type experi sever diseas would
candid consist lumasiran treatment defici
concentr northern africa middl east estim us
popul eu popul slightli larger
estim price us launch base typic cost
greater patient healthcar system transplant
lifelong immunosuppress believ price warrant base
cost typic rare diseas drug immens benefit lumasiran
provid qualiti life patient
inclisiran complet trial track
submit nda fda inclisiran novel inhibitor
product product current market target
therapeut agent repatha praluent monoclon
antibodi inclisiran dose yearli pois potenti domin share
under-penetrated market
inclisiran util alni galnac technolog enhanc stabil chemistri
also mean requir immunosuppress pretreat alnylam
licens inclisiran medicin compani royalti
expect mileston regulatori approv
commerci mileston expect mdco launch inclisiran late
enzym produc liver bind receptor
surfac hepatocyt block normal action receptor
bind absorb cholesterol peripheri
exhibit mechan action inhibitor
there unmet need lack statin adher poor ldl-c manag
despit statin mani patient reach target level
indic need effect therapi manag
current guidanc inhibitor use indic statin ezetimib
enough statin tradit frontlin treatment lower
ldl-c continu howev patient high risk
cardiovascular diseas inhibitor continu attract therapi
reduc amgen fourier trial show reduct -c
continu show linear relationship ldl-c level advers
cardiovascular event indic valu inhibitor
patient risk event impli better price inhibitor
pois take larg share fh/cvd patient popul
mani patient current mab inhibitor stop use day due
annual schedul inclisiran requir bi-annu inject
significantli drive patient adher
exhibit mdco expect potenti target market
medicin compani estim million patient annual fail meet
ldl-c goal even penetr residu market annual
price inclisiran would annual potenti sale inclisiran
rnai therapeut blockbust potenti believ
blood clot imper biolog process respond manag
injuri throughout bodi depend type stimulu clot-form
process activ via intrins extrins pathway upon endothelium
damag chemic releas activ factor xii therebi initi
intrins pathway key enzym intrins cascad lead product
fibrin glycoprotein call factor viii exhibit defici factor viii
limit product fibrin lead excess trauma-induc hemorrhag
well spontan hemorrhag sever case factor viii defici
typic result x-link disord call hemophilia mutat
factor viii gene lead factor viii activ far normal
rang iu per decilit hemophilia genet similar instead
consist defici factor ix sinc factor ix upstream factor viii
factor xi also act factor viii hemophilia gener less sever
drelich et al medscap opco research
sever hemophilia import guid appropri treatment
sever categor three group base percentag normal
factor viii activ sever result frequent spontan
hemorrhag moder result infrequ spontan
hemorrhag mild result trauma-induc post-
surgic bleed current primari mode treatment consist regularli
administr recombin plasma concentr factor viii treatment
modal fertil improv fraught issu recombin
protein exhibit short half-lif result need frequent infus
three time week patient develop inhibitor treatment
prolong use inhibitor highli problemat patient repres
area need treatment hemophilia
alnylam take differ approach treatment hemophilia a/b suit
compani rnai-bas therapi given yet design rnai
upregul product given protein alnylam must find target protein
downregul case protein antithrombin antithrombin normal
action bodi bind inhibit thrombin factor xa factor ixa order
prevent unnecessari clot inhibit product antithrombin
seek upregul activ factor inhibit promot effect
exhibit inhibit thrombin antithrombin
liang et al clinic scienc antithrombin kidney-rel diseas
phase studi structur durat
month factor/prophylact treatment once-monthli inject
fitusiran end studi studi recruit particip singl group
assign open label intern studi locat
particip patient enrol must minimum two bleed episod
past six month requir bypass agent develop inhibitori
antibodi one bleed episod past month requir factor
concentr inhibitori antibodi
trial current enrol may issu full recruit fitusiran
one death due blood clot phase trial ole
fitusiran face competit factor viii ix replac therapi
hemlibra bispecif antibodi market roch valrox gene therapi
hemophilia potenti bla submiss year-end
develop biomarin gene therapi program develop
spark shire
crowd competit landscap fitusiran like go nich
product approv properli fit market address patient
develop inhibitor factor viii ix competitor hemlibra
presenc gene therapi hemophilia space like dampen
enthusiasm regard treatment option remain seen
gene therapi use commerci provid durabl respons
potenti redos
believ safeti profil mechan action crowd competit
landscap right issu sanofi fitusiran small part alnylam stori
find unlik gener signific cash flow compani
alnylam earli stage asset predominantli util esc galnac technolog
except cemdisiran asset continu older esc
cemdisiran origin design atyp hemolyt urem syndrom
discontinu due recruit challeng regulatori approv
phase studi iga nephropathi
iga nephropathi common caus primari glomerulonephr
complement protein implic pathogenesi igan format
pathogen immun complex deposit within
mesangi cell kidney
alnylam partner regeneron advanc cemdisiran combin
pozelimab corpor present alnylam point total
complement-medi diseas cemdisiran could impact
compani phase combo trial plan begin addit ucb
recent bought competitor space
premium factor may indic grow interest
understand treatment complement-medi pathway
trial cemdisiran current enrol expect
durat primari endpoint studi chang baselin
proteinuria like esc-galnac molecul cemdisiran
administ subcutan long durat action
antitrypsin proteas inhibitor involv inhibit variou
enzymesmost notabl neutrophil elastas defici diseas
decreas absent result chronic uninhibit tissu degrad
common present involv breakdown lung tissu
subsequ pulmonari edema mutant z-type chemotact
neutrophil neutrophil elastas lung break elastin connect
tissu within lung pizz phenotyp sever
normal serum level patient two z-type allel
phenotyp often accumul protein within hepatocyt
liver subsequ liver diseas
univers utah genet scienc learn center
alnylam target patient pizz type knock z-type mutant
protein conduct singl ascending- multiple-dos studi aln-
healthi adult patient zz
origin phase halt elev
liver enzym highest dose rnai treatment util esc-galnac
platform alnylam believ improv stabil
chemistri allow dose safer level similar efficaci alnylam
initi phase trial decemb expect data later
true cure defici potenti cur option
includ liver lung transplant direct replac therapi option avail
administ weekli iv also palli option
bronchodil inhal steroid antibiot
arrowhead also rnai asset phase
approach alnylam hope util therapi finit
durat therapi amelior z-aat liver accumul shown high
knockdown efficaci reduct pre-dos serum level
shown knockdown z-aat polym liver week
administr day arwr phase studi healthi individu
signific declin forc expir volum measur lung viabil
remain seen safeti continu move
arrowhead result expect rnai therapeut
phase expect alnylam would superior arrowhead
commerci basi esc platform would allow infrequ dose
schedul alnylam also far develop commerci infrastructur
place go market
alnylam initi phase trial novemb
expect see data later year
alnylam receiv up-front payment compris cash share stock
also elig receiv potenti mileston payment
compani opt option co-develop profit share
also hbv program partner
push hard attract function curea near total remov
hbsag bloodstream compani effect entir
depend willing lawmak payer physician accept
treatment hbv block transcript viral particl get
releas bloodstream howev noth hbv cccdna
reservoir remain hepatocyt stifl hbv cur
treatment thu far forese true cur therapi
assign much success program
rnai treatment angiotensinogen silenc angiotensinogen
precursor angiotensin molecul angiotensin molecul peptid
hormon varieti function relev
angiotensin ii angiotensin ii act central nervou system increas
vasopressin product adren gland produc aldosteron
import function also act venou arteri smooth
muscl caus vasocontrict
angiotensin ii receptor antagonist thiazid diuret calcium channel
blocker antihypertens respons occur patient
adher treatment remain major barrier control blood pressur bp
approxim patient discontinu treatment within two year
trough dose effect may impact adher
present major opportun alnylam given stabil esc
molecul dose allow expect quarterli possibl even
bi-annu dose schedul improv adher
alnylam target resistant/refractori hypertens initi patient subset
go r/r hypertens defin uncontrol blood
pressur despit use antihypertens medic differ class
alnylam state expect popul around individu
unit state initi phase dose began may expect initi
result late phase trial design includ separ experi
placebo compar activ compar
part singl ascend dose compar singl dose
placebo evalu hypertens patient
part evalu hypertens patient control salt intak
administ singl dose compar placebo
part activ compar multipl dose combin
irbesartan placebo compar arm multipl dose activ irbesartan
placebo dose mimick
final part involv obes patient administ multipl dose
irbesartan placebo compar group obes patient
administ multipl dose irbesartan placebo mimick
ibresartan angiotensin ii receptor antagonist act prevent
angiotensin ii bind receptor smooth muscl surround vein
arteri prevent constrict effect would normal facilit
ocular diseas collabor regeneron
alnylam believ crack code administ rnai major
organ specif brain eye yet see preclin data
alnylam program receiv valid regeneron seen
preclin data invest equiti invest
up-front payment alnylam partnership
asset
addit alnylam elig mileston payment earli
clinic develop eye program compani also plan
advanc program direct target introduc mani clinic
develop five-year discoveri period regeneron provid
alnylam per program initi lead candid
identif potenti addit mileston
believ base convers kol amyloid space
addit ttr amyloid element occur brain rare seen
hattr popul surviv long enough diseas
manifest within ttr produc liver also
choroid plexu retin epithelium evid liver transplant
patient mutat accumul ttr amyloid within
brain eye continu produc galnac conjug cours
design target hepatocyt cross blood-brain barrier lipid
nanoparticl may cross blood-brain barrier may amount
small gener therapeut effect may next issu
solv patient surviv long enough suscept brain eye
one addit concern note forese onset impact
clinic trial commerci impli role ttr stave
alzheim diseas research done indic ttr play
major role abduct b-amyloid accumul transport
bbb play role move b-amyloid brain blood
allow transport b-amyloid blood brain ttr highli conserv
evolutionarili mani expert point crossov transport protein
also perform suppos function protein would highli
conserv redund protein theoriz major impact ttr
contribut conserv abil clear b-amyloid
plaqu knockdown ttr potenti health implic
yet see signal howev potenti implic
depend clinic work initi within treatment
alnylam alreadi note interest target amyloid precursor protein
hereditari cerebr amyloid angiopathi expect alnylam leverag exist
expertis ttr also target ttr alnylam state object
first ind late ind per year year thereaft
expect alnylam target diseas small patient popul genet
abnorm implic larger patient popul set
would like reiter complex brain point mani
treatment fail howev high preval genet
factor diseas entir new mechan action rnai treatment
remain cautious optimist potenti rna silenc
halt revers progress mani diseas
alnylam proprietari technolog protect multipl patient famili
includ composit activ rnai agent deliveri platform
chemic modif method treatment patent term
estim extend least expect significantli longer term
around asset yet reach market includ patent
term extens restor
arrowhead obtain gal-nac technolog well patent arrowhead
receiv right technolog issuanc licens obtain
assigne novarti grant licens gene target
limit access certain aspect alnylam technolog knowledg
licens grant access remain
mm except per share data fy product net commerci product development-stag product risk adj vutrisiran/onpattro expansion- givosiran- fitusiaran- inclisiran- lumasiran- net development-stag product rev- net total product net revenu total total oper oper oper margininterest incom litig total pre-tax incom tax benefit net incom sale dilut gaap dilut non-gaap y/i growthdilut share incom net cash oper net cash invest net cash net chang cash ce ce rc ce rc cash market debt market equiti securities- invest equiti secur regulu therapeut account receiv inventory- prepaid expens current total current non-current asset market defer tax assets- oper leas right-of-us assets- properti equip restrict total current liabil account accru oper leas liability- defer -- -- -- -- -defer total current non-current liabil oper leas defer rent net current defer revenu net current long-term total stockhold equiti common addit paid-in accumul comprehens incom accumul total sharehold total liabil sharehold outperform
john maraganor ceo director alnylam sinc prior
alnylam serv offic member manag team
develop millennium respons compani product
franchis oncolog cardiovascular inflammatori metabol diseas
previous vice presid strateg plan prior
gener manag millennium biotherapeut inc former subsidiari
millennium millennium serv director molecular biolog
director market busi develop inc dr maraganor
receiv ms ph biochemistri molecular biolog univers
chicago
jeff poulton recent join alnylam current board eip
pharma inc prior alnylam cfo indigo prior
cfo shire hold ba econom duke univers mba
kelley school busi indiana univers
pushkal garg alnylam sinc join senior vice presid
clinic develop octob prior alnylam vice-president clinic
develop bristol-my squibb prior join industri
attend physician brigham women hospit dr garg earn
univers california san francisco ba biochemistri univers
california berkley
yvonn greenstreet alnylam sinc previous svp
head medicin develop time
svp chief strategi glaxosmithklin board pacira
bioscienc independ director moeli co dndivior
plc ms greenstreet hold mba insead mbchb univers
leed
kevin fitzgerald phd alnylam sinc current chief
scientif offic take posit increas respons within research
develop prior join alnylam dr fitzgerald serv group leader
bristol-my squibb group perform target valid genom
compound toxicolog target discoveri post-doctor work
harvard medic school focu breast cancer hold phd biolog
princeton univers bs genet cornel univers
senior vice presid gener counsel secretari
barri green alnylam sinc hold posit
presid prior alnylam spent two year takeda astrazeneca
gener manag takeda oncolog divis vice-president market
custom servic astrazeneca plc prior time pharmaceut
partner andersen consult llp mr green board acorda
therapeut mr green hold bs industri engin univers
pittsburgh
execut vice presid research develop
akshay vaishnaw md phd alnylam sinc current
evp research develop prior alnylam senior director
medic research serv board visterra inc sinc
member scientif advisori board scholar hold
multipl graduat certif variou universitiesh ph
immunolog univers london dr vaishnaw also mrcp
frcp royal colleg physician uk earn md
univers wale cardiff
execut vice presid gener counsel secretari
ms keat alnylam sinc current evp gener
counsel secretari respons legal ip complianc public
polici govern relat prior alnylam svp millennium
pharmaceut posit previous found ceo
hydra bioscienc svp gener counsel sybas inc ms keat
earn jd univers california hast school law ba
univers california berkeley
board director overview
alnylam board eight independ director director chairman
ceo john maraganor sit board cofound alnylam paul
schimmel phd philip sharp phd remain board michael bonney
chairman board also serv board
sarepta celgen
stock price compani mention report
